Please select the outcome measures that correspond to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age group (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Gender (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Index month (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Height (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Weight (At Baseline); Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Body Mass Index (BMI) (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Treatments (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Comorbidities (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Follow-up (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: History of thrombosis (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Charlson Comorbidity Index (CCI) (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: CCI severity (At Baseline); Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Molecular/diagnosis testing (At Baseline); Distribution of the use of treatments for COVID-19: Anticoagulation (Up to 9 months); Distribution of the use of treatments for COVID-19: Angiotensin-converting enzyme (ACE) inhibitors (Up to 9 months); Distribution of the use of treatments for COVID-19: Angiotensin II receptor blockers (ARBs) (Up to 9 months); Distribution of the use of treatments for COVID-19: ARBs combination (Up to 9 months); Distribution of the use of treatments for COVID-19: Statin (Up to 9 months); Distribution of the use of treatments for COVID-19: HIV protease inhibitor (Up to 9 months); Distribution of the use of treatments for COVID-19: Non-pharmacological treatment (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: Anticoagulation (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: Angiotensin-converting enzyme (ACE) inhibitors (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: Angiotensin II receptor blockers (ARBs) (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: ARBs combinations (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: Statin (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: HIV protease inhibitor (Up to 9 months); Distribution of the use of treatments for COVID-19 symptoms: Non-pharmacological treatment (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: In-hospital death (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: Overall survival (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: Utilization of Extracorporeal membrane oxygenation (ECMO) (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: Utilization of mechanical ventilation (invasive & noninvasive) (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: Utilization of oxygen therapy (Up to 9 months); Distribution of composite outcomes of COVID-19 patients: Intensive care unit/high care unit (ICU/HCU) admission (Up to 9 months)
B: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism (Up to 12 months, at least 6 months); Number of Participants With First Treatment-emergent Major Bleeding (Up to 12 months, at least 6 months)
C: Rate of invasive mechanical ventilation (28 days)
D: All-cause mortality at day 28 (Day 28 from randomization)

Answer: B